HighTower Advisors
PACB icon

HighTower Advisors’s Pacific Biosciences PACB Stock Holding History

HighTower Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,287
Closed -$14.9K – 3964
2026
Q1 		$14.9K Buy
11,287
+1,184
+12% +$2.12K ﹤0.01% 3772
2025
Q4 		$18.9K Sell
10,103
-45
-0.4% -$86 ﹤0.01% 3613
2025
Q3 		$13K Hold
10,148
– – ﹤0.01% 3690
2025
Q2 		$12.6K Sell
10,148
-963
-9% -$1.11K ﹤0.01% 3635
2025
Q1 		$13.1K Sell
11,111
-2,692
-20% -$4.13K ﹤0.01% 3541
2024
Q4 		$25.3K Sell
13,803
-2,795
-17% -$5.46K ﹤0.01% 3522
2024
Q3 		$26K Sell
16,598
-8,318
-33% -$13.7K ﹤0.01% 3487
2024
Q2 		$32K Sell
24,916
-19,505
-44% -$39.4K ﹤0.01% 3361
2024
Q1 		$165K Sell
44,421
-2,136
-5% -$12.5K ﹤0.01% 3037
2023
Q4 		$458K Sell
46,557
-25,540
-35% -$209K ﹤0.01% 2386
2023
Q3 		$601K Sell
72,097
-6,244
-8% -$71.4K ﹤0.01% 2104
2023
Q2 		$1.04M Sell
78,341
-11,565
-13% -$141K ﹤0.01% 1729
2023
Q1 		$1.04M Buy
89,906
+3,183
+4% +$31.6K ﹤0.01% 1646
2022
Q4 		$708K Sell
86,723
-21,415
-20% -$185K ﹤0.01% 1882
2022
Q3 		$630K Sell
108,138
-52,285
-33% -$300K ﹤0.01% 1880
2022
Q2 		$703K Sell
160,423
-48,232
-23% -$293K ﹤0.01% 1853
2022
Q1 		$1.9M Buy
208,655
+117,770
+130% +$1.36M ﹤0.01% 1406
2021
Q4 		$1.86M Buy
90,885
+9,646
+12% +$233K ﹤0.01% 1398
2021
Q3 		$2.08M Sell
81,239
-1,321
-2% -$39.1K 0.01% 1236
2021
Q2 		$2.88M Sell
82,560
-10,253
-11% -$298K 0.01% 1036
2021
Q1 		$3.09M Buy
92,813
+78,513
+549% +$2.75M 0.01% 916
2020
Q4 		$371K Buy
+14,300
New +$243K ﹤0.01% 1796
2017
Q3 		– Sell
-27,785
Closed -$101K – 2329
2017
Q2 		$101K Buy
27,785
+7,225
+35% +$29.1K ﹤0.01% 1958
2017
Q1 		$94K Buy
+20,560
New +$101K ﹤0.01% 1878

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HighTower Advisors's PACB Position: Q2 2026 in Review

HighTower Advisors sold out of Pacific Biosciences (PACB) in Q2 2026, closing a stake of 11,287 shares — an estimated $14.9K sold.

HighTower Advisors first reported a position in PACB in Q1 2017 and held it in 24 quarters. The position peaked at $3.09M in Q1 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • HighTower Advisors reported no remaining Pacific Biosciences position as of Q2 2026 after selling out during the quarter.
  • HighTower Advisors sold 11,287 Pacific Biosciences shares in Q2 2026, an estimated $14.9K.
  • HighTower Advisors first reported a position in Pacific Biosciences in Q1 2017 and held it in 24 quarters.
  • HighTower Advisors's Pacific Biosciences position peaked at $3.09M in Q1 2021.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.